{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:31:34Z","timestamp":1778171494453,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jmoldx.2025.08.009","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T19:32:12Z","timestamp":1758828732000},"page":"1213-1223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Validation and Clinical Utility of a Pan-Cancer Circulating Tumor DNA Assay as a First-Approach Test"],"prefix":"10.1016","volume":"27","author":[{"given":"Nisha","family":"Kanwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Campion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber R.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragana","family":"Milosevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Sosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonina A.","family":"Wojcik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-2526","authenticated-orcid":false,"given":"Kevin C.","family":"Halling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kandelaria M.","family":"Rumilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Chun","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6068-5505","authenticated-orcid":false,"given":"Zhiyv","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0424-7572","authenticated-orcid":false,"given":"Katherine B.","family":"Geiersbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret A.","family":"DiGuardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin R.","family":"Kipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0276-9430","authenticated-orcid":false,"given":"Gang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2025.08.009_bib1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"Aberle","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/ejcts\/ezv172","article-title":"Development of a prediction model and risk score for procedure-related complications in patients undergoing percutaneous computed tomography-guided lung biopsy","volume":"48","author":"Anzidei","year":"2015","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1126\/science.1253462","article-title":"Spatial and temporal diversity in genomic instability processes defines lung cancer evolution","volume":"346","author":"de Bruin","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib6","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/0974-2077.150734","article-title":"Principles and methods of preparation of platelet-rich plasma: a review and author's perspective","volume":"7","author":"Dhurat","year":"2014","journal-title":"J Cutan Aesthet Surg"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib8","doi-asserted-by":"crossref","first-page":"16156","DOI":"10.1073\/pnas.202610899","article-title":"Digital karyotyping","volume":"99","author":"Wang","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004742","article-title":"Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing","volume":"4","author":"Leary","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91974-x","article-title":"Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer","volume":"11","author":"Dedeurwaerdere","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib11","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.gim.2022.01.001","article-title":"Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)","volume":"24","author":"Horak","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib13","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3390\/cancers15051578","article-title":"Evolution of the targeted therapy landscape for cholangiocarcinoma: is cholangiocarcinoma the 'NSCLC' of GI oncology?","volume":"15","author":"Gupta","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10549-019-05349-y","article-title":"PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy","volume":"177","author":"Jacot","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jmoldx.2015.02.001","article-title":"Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology","volume":"17","author":"Gold","year":"2015","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib16","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/clinchem\/hvad194","article-title":"Critical factors in the analytical work flow of circulating tumor DNA-based molecular profiling","volume":"70","author":"van der Leest","year":"2024","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib19","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.3390\/ijms23084441","article-title":"Circulating tumor DNA in precision oncology and its applications in colorectal cancer","volume":"23","author":"Arisi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4143\/crt.2022.1026","article-title":"Clinical circulating tumor DNA testing for precision oncology","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082277","article-title":"Clonal hematopoiesis in liquid biopsy: from biological noise to valuable clinical implications","volume":"12","author":"Chan","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41698-021-00202-2","article-title":"Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA","volume":"5","author":"Finkle","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib23","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib27","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib28","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41698-023-00376-x","article-title":"Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge","volume":"7","author":"Keane","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jtho.2016.08.145","article-title":"Combinational analysis of FISH and immunohistochemistry reveals rare genomic events in ALK fusion patterns in NSCLC that responds to crizotinib treatment","volume":"12","author":"Li","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.lungcan.2016.11.001","article-title":"Detection of ALK rearrangements in 4002 Russian patients: the utility of different diagnostic approaches","volume":"103","author":"Demidova","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.21147\/j.issn.1000-9604.2016.05.04","article-title":"Detection of ALK translocation in non-small cell lung carcinoma (NSCLC) and its clinicopathological significance using the Ventana immunohistochemical staining method: a single-center large-scale investigation of 1,504 Chinese Han patients","volume":"28","author":"Yang","year":"2016","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s12885-016-2646-x","article-title":"Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer","volume":"16","author":"Mattsson","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/JTO.0000000000000061","article-title":"HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma","volume":"9","author":"Hong","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41576-021-00338-8","article-title":"Clinical cancer genomic profiling","volume":"22","author":"Chakravarty","year":"2021","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib37","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1373\/clinchem.2014.235457","article-title":"Brain tumor mutations detected in cerebral spinal fluid","volume":"61","author":"Pan","year":"2015","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib38","first-page":"253","article-title":"Circulating tumor DNA: a resuscitative gold mine?","volume":"3","author":"Huang","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020362","article-title":"Treatment of intrahepatic cholangiocarcinoma--a multidisciplinary approach","volume":"14","author":"Krenzien","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib41","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/14737140.2024.2387612","article-title":"Targeted therapies in advanced biliary malignancies: a clinical review","volume":"24","author":"Grewal","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jmoldx.2025.08.009_bib42","article-title":"Routine clinical liquid biopsy testing for solid tumors delivers the promise of minimally invasive detection of genomic variants with a faster turnaround time","volume":"9","author":"Wang","year":"2025","journal-title":"JCO Precis Oncol"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157825002211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157825002211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:14:47Z","timestamp":1763770487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157825002211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1525157825002211"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2025.08.009","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation and Clinical Utility of a Pan-Cancer Circulating Tumor DNA Assay as a First-Approach Test","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2025.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}